KRAS and neoplasm: The manufacturers of both the Therascreen KRAS and Cobas KRAS and BRAF assays state that less than 5% mutant DNA can be detected using 100 ng gDNA isolated from FFPE tissue samples with at least 10% tumor cells on the slide.